Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That paves the way for ESS to begin study in 2017. Go Patient care.
Bye bye AMBS.
I am calling it before the end of the year. Q city.
It sounds like a good time to sell, if I owned this stock.
It is true that the chart is primed for a move up. I just do not know what would help stimulate that move.
Note, I did write, if the trial happens under AMBS. In general, I am betting the trial will start next year, unless the impending AMBS bankruptcy somehow ties it up.
Strangely the stock did base at the four cent level, and is now firmly above the 50 day MA, which is support.
Given the position of the company, I hope that if you bought at four cents, you sold at five to six.
The next leg must be down, since there is no reason for it to go up.
Interesting that the stock did finally base. I did not take my own advice and buy in the fours. Oh well.
It says the three sites are not yet recruiting. Note that the .gov processed that post yesterday. I would think that the trial will actually run in 2017 and finish in 2018, if the trial happens under AMBS.
Yes you have to wonder if they will get to keep ESS
The diagnostics have no value.
Only Ess has value.
Manf could have value if someone spent a billion on the crap shoot.
http://stockcharts.com/h-sc/ui?s=AMBS&p=D&b=5&g=0&id=p32905034268
I do not believe the stock has had a solid two month basing in a long time.
The pps broke the MA, there is an uptick in the MACD and your favorite pmo.
The pps is behaving as if the market is expecting good news.
That said, the stock could go up or down at this point.
THE Elephant in the room is not doing to well. No bouncing, or breathing, or eating, just rotting.
It is going to be Nov 2012 at some point. I believe that Sason will keep it alive because of ESS. I would.
All of the rest has no immediate value.
https://clinicaltrials.gov/ct2/show/record/NCT02439125
This states June 2017 is the final data collection date for primary outcome measure of the Eltoprazine study.
Without an infusion for and beginning of the ESS study, AMBS will not be around.
I do expect ESS to get studied. The material is apparently readied for the study to begin, per AMBS PR in the late winter.
Estimated Completion Date December 2017
Estimated Primary Completion Date June 2017 (final data collection date for primary outcome measure)
No funding for ESS study, i suppose.
Well, it is a trading vehicle. Only that. Otherwise, this is entirely correct. I doubt that there is enough cash in ESS to make up for the rest of the dogs
And this happened once before, they put $30 million into MANF that time.
I wonder if they will get to do it in another ten years, why not.
How the other company is run is not important.
I do think this will decrease AMBS costs, so that is good for AMBS.
I think that the dx company is in it for their salaries and bonuses just like AMBS. Again, that is not important, unless you have dx stock.
OF course, AMBS now owns a lot of DX stock, but everyone knows that stock is worthless.
Avant Diagnostics, Inc., formerly known as American Liberty Petroleum Corp., is diagnostic company. The Company focuses on the commercialization of a series of microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. The Company provides panel biomarker screening test for ovarian cancer. The Company's premier product is OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer.
This is funny, an ambs clone, avdx bought the useless arm of AMBS for useless stock.
Now, this DOES get the cost of the dx wing out of AMBS. That is actually a good thing. ( if that is the case )
The DX wing has been sent to die at AVDX.
And if the float is only 2% of the total, than it is not really a public company.
This penny world is interesting.
Long live Lympro, long live MSDX, long live neuropro, and whatever else they can think up. Let's see, a test for AD, BD, CD, DD, and ED. or something like that.
Boy, has the market closed, I want to put in an order on this wonderful company. I am convinced.
I agree with all of that. The comment before ( of mine ) was a joke.
And the tax credits amount to gazillions. Christie is all about giving away the store.
Apparently so, since you think so. Or something like that.
The Christie remark was about his weight. He sat on the tax breaks, get it.
lol.
All in all, the AMBS mngt is the very worst I have ever seen. If I had any ties to GC and co, I would not own up to them.
El heffo is the Governor of my home state, and my folks still live in the nice part of Camden County, which of course does not include Camden, by any means.
Chip Kelly just moved in a few miles away, to an even nicer part of Camden county. ( Eagles head coach )
I hear Gov Christie is sitting on those tax credit deals.
Are you serious about the shares, and letting people go, and GC living in PA?
ah, well,if that were correct we would all be rich.
this is pretty good, the pps was six cents just a little while ago, now it is 38 cents.
( I know about the RS, this was sarcasm )
See thru equity. I see through everything they say, they have so much credibility.
As far as lympro is concerned, well, the cash is not coming any time soon.
oh.
AFAIK, AMBS and GC are radioactive. Let's get ESS done first and then see what happens.
You may be interested in the following quote from the release on the 4th.
To approve an amendment to the Company’s Articles of Incorporation to increase the Company’s authorized shares of common stock from 35,000,000 to 150,000,000;
2 To approve an amendment to the Company’s 2014 Stock Plan to increase the number of shares of common stock authorized for issuance thereunder from 1,025,868 to 7,500,000; and
7 mill, to 13 mill to 35 mill, to 150 mill, to ????
There goes the neighborhood.
not buying, but looking for an entry point. ESS is a real product, but the rest of the company is either worthless, or much too expensive to fund.
Six weeks plus of stable pps will begin to interest me.
wow, 1.3 Billion pre RS shares in one offering. That is the dawn of a new new day.
A billion here and a billion there, pretty soon, you have more worthless shares.
I do not know how much of the A/S remain, but with the pps tumbling, they will need millions of shares a month just to fund the company.
Yep, the next down day is the buying day. Iow, below $1 once again.
.90 is actually .006 a new all time LOW. Go Ambs. A real buying opportunity is coming up.
http://stockcharts.com/h-sc/ui?s=AMBS&p=D&b=5&g=0&id=p78459191750
So, real two to three day buying opportunities come when the pps is outside the BBs, as you can see from the chart.
Before today, the pps was hanging in the middle of the lower range of BBs. I could not believe it when I saw that yesterday.
Hairy Nevi incidence
CNN are present at birth or soon thereafter.
The melanin pigment in the surface is apparent.
Delay in appearance of surface pigmentation may occur from age 1 month to 2 years in the rare "tardive" type.
A CNN larger than 9.9 cm in diameter occurs in 1 per 20,000 newborns; a CNN larger than 20 cm in diameter occurs in 1 per 500,000 newborns.[10, 11]
Actually the first actionable event about which I am aware was from Nov 9 2012 when GC said MJFF agreed with AMBS when they do not. It is interesting that AMBS on its own still makes that claim. ( details prn. )
In the meantime, an SEC complaint, covering their actions all the way back to Jan 2013 could easily sink the company.
They were almost sunk already by the DTIC chill.
Interestingly, they did have a CEO before this, and while I was not around then, I do not hear about these type problems from that time period.
The normal way to get funding before going public is to go to a venture capitalist.
Then you get your company going and you list on a real exchange.
Doing it this way rarely works.
However, all of the pennies do raise money this way. So there is that.
In this case, there are multiple actionable actions on the part of the company, should they ever have enough money to go around to actually have any to divide up between those who were harmed.
So, Discover could get a better return by shorting the stock? details please.
It is going to take a positive catalyst. There is a lot of damage to the stock.
At 1.1 the stock got back to its historic lows. It was a great run of lies. $1.1 is $.0073333
or .07 cents. Is this all time low going to hold? Inquiring minds want to know.
That was also the day to sell. When I published that stuff. I had to yell at my Brother, because he is not a biotechy, like me, but he finally did.
I don't yell at brother very often, so he got it.
You will remember that it was me who actually found the unreported data on Lympro in the body of the poster. LOL. The summary had nothing to do with the data. OMG.
One other person that I ran into, noticed it, after I did on another board.
That was the worst of the claims, the other data presented there is as plain as day as well. However.
My yelling here did not do as well.
Also, since I keep all of my emails, unlike some professionals that might not be running for President any longer, I am sure that I have the emails from back in early 2013 from GC noting how the company had important data to present, at that Jan 2013 meeting and what not.
The most telling emails were when GC said, this company is very important to my family. ( words to that affect. )
The poster who just reiterates that this is a penny stock is not a biotechy. This is a penny stock that has toxic financing, like all of them. Some of the penny stocks make it, but not many, but they all have toxic financing. That is not actionable.
You may want to go over the details of what AMBS did with the Lympro presentations last year. They are in my stickie.
That is actionable it seems to me.
Also, back in Jan 2013, they kept saying that the company is in possession of important data, causing a runup, and then revealed that the study had FOUR rats in it. Oh, it will have to be done again, lol
THere are others, but they are the two that come to mind first.
As noted by others, the pipeline is undervalued because of the real possibility that it cannot possibly be funded.
30 million from whom? They can get tax credits, but they are not getting any money out front from the Govt, unless they get a separate NIH grant. Certainly the folks in Miami are top researchers and so they may well attract cash. AMBS can only attract flies, and offers to buy stuff.
Rutgers and the outfit in Washington will attract cash for the ESS study.
http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:pnf_charts:pnf_bearish_bd
There was a descending Triple bottom breakdown in the chart. That is essentially TWO successive double bottom breakdowns.
So there is NO reason to think the pps is bottoming at this point.
The ppo DOVE on that day, and the MACD is now negative as well. The RSI is oversold, but well, its been that way for some time now.
The pps is walking down the lower BB.
With this picture, I would think that one dollar is the next stop, equivalent, more or less to the all time low.
IOW, the RS has been a disaster. However, they needed to bring the AS from 2 Billion to Five Billion in order to fund the company for the next year, and so the gambled on an RS uplisting and so on.
In other words, they bought WAY too much stuff and are now paying for it big time.